

Onco-surgical Strategies in Pancreatic Ductal Adenocarcinoma

Irinel Popescu^{1,2}, Traian Dumitrascu^{1,3}

¹“Dan Setlacec” Center of General Surgery and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania

²“Titu Maiorescu” University, Bucharest, Romania

³“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an important healthcare problem because is a leading cause of death by cancer. PDAC is a highly lethal disease with a very dismal prognosis. Most patients present advanced disease at diagnosis. The management of a patient diagnosed with PDAC should be discussed in a multidisciplinary team in high-volume centers. Pancreatectomy represents the single hope of long-term survival for a patient with PDAC but the resectability rate is less than 20% of the cases. Several progresses were observed in the last years regarding the surgical and oncological approach for PDAC. The aim of the paper is to make a brief review of the current onco-surgical strategies available for patients with PDAC.

Key words: pancreatic ductal adenocarcinoma, pancreatectomy, adjuvant chemotherapy, neoadjuvant therapy, survival